(Q54303287)

English

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung c

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

0 references

Armando Santoro

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

P Schöffski

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

B Besse

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

T Gauler

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

M J A de Jonge

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

G Scambia

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

C Davite

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

M G Jannuzzo

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

A Petroccione

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

J-P Delord

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

8 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

598-607

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Mitotic kinases as regulators of cell division and its checkpoints

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Chromosomal passengers and the (aurora) ABCs of mitosis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Aurora-kinase inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Cell-cycle targeted therapies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Aurora kinase inhibitors: progress towards the clinic

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Aurora kinase inhibitors as anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Danusertib, an aurora kinase inhibitor

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU566

21 January 2018

Identifiers

10.1093/ANNONC/MDU566

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25488684%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54303287&oldid=1122796455"